Wyeth v. Levine
The Supreme Court ruled that FDA approval of a drug's label does not automatically shield a drug maker from state lawsuits claiming the label failed to warn adequately about a specific method of injecting the drug.
The decision preserved state juries' role in policing drug safety alongside the FDA, rejecting the drug maker's argument that federal regulation alone should control what warnings appear on a drug label.
“By contrast, we have no occasion in this case to consider the pre-emptive effect of a specific agency regulation bearing the force of law.”
The majority clarifies its ruling does not address whether a formal FDA regulation could pre-empt state claims.
How it got here: A Vermont jury awarded damages to Levine; the trial court and Vermont Supreme Court rejected Wyeth's pre-emption defense; Wyeth appealed to the U.S. Supreme Court.
The Case in Depth
What happened
A Vermont clinician injected the anti-nausea drug Phenergan directly into a woman's vein using the "IV-push" method rather than the safer "IV-drip" method. The drug entered her artery, causing gangrene, and doctors amputated her forearm. She sued the drug's manufacturer, Wyeth, arguing its label should have warned more strongly against IV-push administration.
The question before the Court
When the FDA had approved a drug's warning label, could a state jury still find the label legally inadequate and award damages to an injured patient?
The Court's answer
No — the Court ruled that FDA approval of Phenergan's label did not shield Wyeth from Diana Levine's state-law lawsuit. Federal regulations let drug makers unilaterally strengthen warning labels before receiving FDA approval, so it was not impossible for Wyeth to comply with both state and federal law. And Congress never intended FDA oversight to be the exclusive means of ensuring drug safety, having repeatedly declined to bar such state lawsuits.
The Court gave no weight to a 2006 FDA statement claiming state suits interfere with its mission, because that statement reversed decades of the agency's own contrary position without proper public input. Because no formal FDA regulation specifically addressed IV-push warnings, the state jury's verdict could stand alongside federal regulation rather than conflicting with it.
Curious how the Court got there? See the step-by-step legal reasoning →
Why it matters
Patients injured by inadequately labeled prescription drugs retain the ability to sue drug manufacturers in state court even after FDA approval of a label. Drug companies must continue monitoring safety data and strengthening warnings on their own initiative, since FDA approval alone will not protect them from liability.
What changes now
The judgment of the Vermont Supreme Court is affirmed, meaning Diana Levine keeps her jury award. Drug manufacturers must continue to monitor and strengthen warning labels on their own initiative rather than relying solely on FDA approval as a defense against state lawsuits. This is a final merits decision, not subject to further review.
What this does not decide
The Court explicitly did not decide whether a state rule banning IV-push administration entirely would be pre-empted, nor did it address what would happen if a formal FDA regulation (rather than a mere preamble) specifically addressed the warning at issue.
Concurrences and dissents
Concurrence — Justice Breyer
Justice Breyer emphasized that the Court left open whether a specific FDA regulation with the force of law could pre-empt state tort claims in the future. He noted state tort law can both help the FDA uncover drug hazards and potentially interfere with the FDA's labeling choices, and suggested the FDA could still act to give its determinations pre-emptive effect through proper regulations.
Concurrence — Justice Thomas
Justice Thomas agreed the label was not pre-empted but refused to endorse the Court's broader 'purposes and objectives' pre-emption doctrine, which he views as unconstitutional because it lets courts override state law based on inferred congressional purposes not found in statutory text rather than the text itself.
Dissent — Justice Alito
“This case illustrates that tragic facts make bad law.”The dissent's opening line framing its objection to the majority's ruling.
Justice Alito argued the case is squarely controlled by Geier v. American Honda: the FDA had extensively studied and struck a considered balance permitting IV-push administration of Phenergan, and a state jury should not be allowed to countermand that expert safety judgment. He would have found the claim pre-empted and reversed.
How the Court got there
The legal reasoning, step by step
- The Court first considered whether it was physically impossible for Wyeth to comply with both federal and state law. It found that FDA regulations let a manufacturer unilaterally strengthen a drug's warning label before receiving formal FDA approval, through a mechanism called the 'changes being effected' rule.
- Because Wyeth could have used that mechanism to add a stronger IV-push warning without violating federal law, and had not shown the FDA would have rejected such a change, the Court concluded compliance with both state and federal duties was not impossible.
- The Court then asked whether the state lawsuit stood as an obstacle to the purposes and objectives Congress intended for federal drug regulation. It reviewed the history of the federal drug law and found that Congress had repeatedly declined to add a provision shielding drug labeling decisions from state lawsuits, even though it did so for medical devices.
- The Court gave little weight to a 2006 FDA preamble asserting that state lawsuits interfere with the agency's mission, because the FDA adopted that position abruptly, without notice-and-comment input from the public, and it contradicted the agency's own longstanding view that state tort suits complement federal regulation.
- The Court distinguished this case from Geier v. American Honda Motor Co., where a formal federal regulation with the force of law reflected a specific safety tradeoff; here, no such formal regulation addressed the specific warning at issue, so state law was not displaced.
Doctrinal impact
Cases affected by this decision
Distinguishes Geier v. American Honda Motor Co. (529 U.S. 861)
The Court said this case differs because no formal federal regulation with the force of law addressed the specific warning at issue.